União Europeia - português - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

b. braun melsungen a.g. - lípidos - emulsão para perfusão - associação - triglicéridos do ácido omega-3 20 mg/ml ; Óleo de soja refinado 80 mg/ml ; triglicéridos de cadeia média 100 mg/ml - fat emulsions - n/a - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

b. braun melsungen a.g. - lípidos - emulsão para perfusão - associação - triglicéridos do ácido omega-3 20 mg/ml ; Óleo de soja refinado 80 mg/ml ; triglicéridos de cadeia média 100 mg/ml - fat emulsions - n/a - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

b. braun melsungen a.g. - lípidos - emulsão para perfusão - associação - triglicéridos do ácido omega-3 20 mg/ml ; Óleo de soja refinado 80 mg/ml ; triglicéridos de cadeia média 100 mg/ml - fat emulsions - n/a - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

b. braun melsungen a.g. - lípidos - emulsão para perfusão - associação - triglicéridos do ácido omega-3 20 mg/ml ; Óleo de soja refinado 80 mg/ml ; triglicéridos de cadeia média 100 mg/ml - fat emulsions - n/a - duração do tratamento: curta ou média duração

União Europeia - português - EMA (European Medicines Agency)

pacira ireland limited - bupivacaine - acute pain - amides, anesthetics, local - exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.

União Europeia - português - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - cloridrato de doxorrubicina - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - agentes antineoplásicos - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

União Europeia - português - EMA (European Medicines Agency)

insmed netherlands b.v. - amikacin sulfate - infecções respiratórias - antibacterianos para uso sistémico, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

egis pharmaceutical, plc - rosuvastatina + ezetimiba - cápsula - 40 mg + 10 mg - rosuvastatina zinco 42.72 mg ; ezetimiba 10 mg - rosuvastatin and ezetimibe - n/a - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

egis pharmaceutical, plc - rosuvastatina + ezetimiba - cápsula - 40 mg + 10 mg - rosuvastatina zinco 42.72 mg ; ezetimiba 10 mg - rosuvastatin and ezetimibe - n/a - duração do tratamento: longa duração